These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 38600789

  • 1. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
    Marshall SA, Siebenmorgen LE, Youngen K, Borders T, Zaller N.
    J Prim Care Community Health; 2024; 15():21501319241246359. PubMed ID: 38600789
    [Abstract] [Full Text] [Related]

  • 2. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
    Mattocks KM, Moore DT, Wischik DL, Lazar CM, Rosen MI.
    J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
    [Abstract] [Full Text] [Related]

  • 3. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH, Cales SC, Shreffler J, Huecker MR.
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [Abstract] [Full Text] [Related]

  • 4. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
    Aronowitz SV, Engel-Rebitzer E, Dolan A, Oyekanmi K, Mandell D, Meisel Z, South E, Lowenstein M.
    Harm Reduct J; 2021 Nov 25; 18(1):119. PubMed ID: 34823538
    [Abstract] [Full Text] [Related]

  • 5. Patient perceptions of and experiences with stigma using telehealth for opioid use disorder treatment: a qualitative analysis.
    Couch JV, Whitcomb M, Buchheit BM, Dorr DA, Malinoski DJ, Korthuis PT, Ono SS, Levander XA.
    Harm Reduct J; 2024 Jun 27; 21(1):125. PubMed ID: 38937779
    [Abstract] [Full Text] [Related]

  • 6. Use of Telehealth for Opioid Use Disorder Treatment in Safety Net Primary Care Settings: A Mixed-Methods Study.
    Bailey SR, Wyte-Lake T, Lucas JA, Williams S, Cantone RE, Garvey BT, Hallock-Koppelman L, Angier H, Cohen DJ.
    Subst Use Misuse; 2023 Jun 27; 58(9):1143-1151. PubMed ID: 37170596
    [Abstract] [Full Text] [Related]

  • 7. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
    Jones CM, Diallo MM, Vythilingam M, Schier JG, Eisenstat M, Compton WM.
    Drug Alcohol Depend; 2021 Aug 01; 225():108783. PubMed ID: 34049102
    [Abstract] [Full Text] [Related]

  • 8. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM.
    JAMA Psychiatry; 2022 Oct 01; 79(10):981-992. PubMed ID: 36044198
    [Abstract] [Full Text] [Related]

  • 9. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L, Sousa J, Raja P, Mehrotra A, Barnett M, Huskamp HA.
    J Subst Abuse Treat; 2020 Nov 01; 118():108124. PubMed ID: 32893047
    [Abstract] [Full Text] [Related]

  • 10. Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation.
    Lott AM, Danner AN, Malte CA, Williams EC, Gordon AJ, Halvorson MA, Saxon AJ, Hagedorn HJ, Sayre GG, Hawkins EJ.
    J Addict Med; 2020 Nov 01; 17(4):e262-e268. PubMed ID: 37579107
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
    Lin LA, Zhang L, Kim HM, Frost MC.
    Am J Psychiatry; 2022 Oct 01; 179(10):740-747. PubMed ID: 35899380
    [Abstract] [Full Text] [Related]

  • 15. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM, Verrastro G, Fusco CW, Wilson CG, Ostrach B.
    J Rural Health; 2021 Jun 01; 37(3):467-472. PubMed ID: 33720447
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV, Levin FR, Reilly MP, El-Bassel N.
    J Subst Abuse Treat; 2021 Mar 01; 122():108196. PubMed ID: 33221125
    [Abstract] [Full Text] [Related]

  • 19. Defining and supporting high-quality telehealth for patients with opioid use disorder: The promise and potential pitfalls of telehealth expansion.
    Frank CJ, Lin LA.
    Subst Abus; 2022 Mar 01; 43(1):1370-1373. PubMed ID: 36222798
    [Abstract] [Full Text] [Related]

  • 20. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA, Sarpong A, Sistad R, Roth C, Banducci AN, Simpson T, Hyde J, Davenport M, Weisberg R.
    J Subst Use Addict Treat; 2024 Jan 01; 156():209188. PubMed ID: 37866437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.